𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C

✍ Scribed by Raymond T. Chung; Fred F. Poordad; Tarek Hassanein; Xiaolei Zhou; Ellen Lentz; Avinash Prabhakar; Adrian M. Di Bisceglie


Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
773 KB
Volume
52
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis


Patients receiving therapy for chronic hepatitis C virus (HCV) infection frequently experience cytopenias and weight loss. We retrospectively assessed the pharmacodynamic effects of pegylated interferon (PEG-IFN) alfa-2a and ribavirin by evaluating the relationship between changes in hematologic parameters, body weight, and virologic response. Patients with HCV genotypes 1, 4, 5, or 6 receiving 24 or 48 weeks of PEG-IFN alfa-2a and ribavirin therapy were pooled from four phase 3/4 trials. Maximum decreases in hemoglobin level, neutrophil count, platelet count, and weight during therapy were assessed according to virologic response category (sustained virologic response [SVR], relapse, breakthrough, and nonresponder) and race/ethnicity. Of 1,778 patients analyzed, more than half were male, non-Hispanic Caucasian, and infected with HCV genotype 1; had a baseline HCV RNA >800,000; and had alanine aminotransferase levels 3 3 the upper limit of normal. Virologic responders (SVR, relapse, and breakthrough) experienced greater maximum decreases from baseline in hemoglobin level, neutrophil count, platelet count, and weight compared with nonresponders; however, no clear trend was observed between SVR, relapse, and breakthrough. After adjusting for drug exposure and treatment duration, only decreases in neutrophil count remained associated with virologic response. Significantly greater declines in neutrophil (P < 0.0001) and platelet (P < 0.005) count were observed at weeks 4, 12, and 24 of therapy in virologic responders compared with nonresponders. This difference between responders and nonresponders was also observed among racial/ ethnic groups, although statistical significance was not consistent across all groups. Conclusion: This post hoc analysis of HCV patients treated with PEG-IFN alfa-2a and ribavirin shows that maximum decreases from baseline in hematologic parameters and weight loss were associated with virologic response. However, after adjusting for drug exposure and accounting for duration of therapy, only neutropenia was independently associated with virologic response. (


📜 SIMILAR VOLUMES


Response to pegylated interferon alfa-2a
✍ Hesham El Makhzangy; Gamal Esmat; Mohamed Said; Maissa ElRaziky; Soheir Shouman; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

## Abstract The safety and efficacy of pegylated interferon (PEG‐IFN) alfa‐2a and ribavirin were studied among patients treated for genotype 4 chronic hepatitis C. Ninety‐five patients with chronic hepatitis C genotype 4 were treated with PEG‐IFN alfa‐2a (180 µg/week) plus ribavirin (≥11 mg/kg/day)

Randomized controlled trial of pegylated
✍ Khoa D. Lam; Huy N. Trinh; Son T. Do; Thuan T. Nguyen; Ruel T. Garcia; Tuan Nguy 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB 👁 2 views

Hepatitis C virus (HCV) genotype is an important criteria in determining duration of therapy and predictor of sustained virologic response (SVR) to pegylated interferon (PEG IFN) and ribavirin (RBV) therapy. Optimal duration of therapy for patients with HCV genotype 6 is not known. We conducted a mu

Pegylated interferon alpha-2b plus ribav
✍ Sanaa M. Kamal; Samer S. El Kamary; Michelle D. Shardell; Mohamed Hashem; Imad N 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 251 KB 👁 2 views

In patients chronically infected with hepatitis C virus (HCV) genotype 4, the optimum duration of therapy and the predictors of sustained virologic response (SVR) have not been adequately determined. In this study, 358 patients with chronic hepatitis C genotype 4 were randomly assigned to pegylated

Pegylated interferon alfa and ribavirin
✍ Olav Dalgard; Kristian Bjøro; Helmer Ring-Larsen; Einar Bjornsson; Mona Holberg- 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 211 KB 👁 1 views

A recent nonrandomized pilot trial showed that hepatitis C virus (HCV) patients with genotype 2/3 and rapid virological response (RVR) had a 90% sustained virological response (SVR) rate after 14 weeks of treatment. We aimed to assess this concept in a randomized controlled trial. In the trial, 428

Analysis of clinical and virological fac
✍ Dr. J. A. Garson; K. Whitby; R. Deaville; S. Brillanti; M. Foli; C. Masci; M. Mi 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 508 KB

## Abstract Interferon alpha (IFN‐α) therapy is currently the treatment of choice for chronic hepatitis C (HCV) infection, but it fails to achieve a sustained response in approximately 75% of those treated. The factors which determine whether or not an individual will respond to IFN‐α are uncertain

Neutralizing antibodies to interferon-α
✍ Philippe Halfon; Sophie Pérusat; Marc Bourlière; Jean-Pierre Bronowicki; Pascale 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

## Abstract A lack of antiviral response in patients with chronic hepatitis C treated with pegylated (PEG)‐interferon (IFN)‐α‐2a + ribavirin (RIBA) may be explained by neutralizing antibodies to IFN‐α‐2a. The aim of this study was to assess neutralizing antibodies to IFN‐α‐2a and IFN levels in non‐